Boston- and London-based Zoe, a nutrition and health tracking app, raised £25M led by Accomplice at a £209M valuation, after closing a £48M Series B in May 2021
Context & Ripple Effects
Zoe is extending its Series B rather than raising a fresh round: after closing a £48M Series B in May 2021, it has added £25M led by Accomplice at a £209M valuation — an 18-month gap between rounds and a smaller check than its prior one, in a funding climate where London startups like Zapp were still pulling $200M Series Bs earlier in 2022 but late-year rounds have tightened.
The competitive frame matters: UK-based Oviva raised an $80M Series C in September 2021 for app-delivered personalized diet and lifestyle advice ($80M Series C), so Zoe's extension lands in a nutrition-tech category where rivals have already secured larger war chests.
First-order effects
- Accomplice leads Zoe's £25M extension at a £209M valuation, giving the Boston- and London-based company runway beyond its May 2021 £48M Series B without pricing a new round.
Second-order effects
- Oviva, already funded at Series C scale, faces a capitalized direct rival in app-based personalized nutrition, pushing both toward differentiation on clinical credibility and user outcomes rather than user acquisition alone.
Third-order effects
- If extension rounds keep substituting for new priced rounds across consumer health, the sector's capital structure shifts toward longer Series B runways and later proof points before Series C — a pattern investors will apply when sizing the next Oviva- or Zoe-class raise.
The trend: Consumer health apps are bridging the 2022 funding slowdown with Series B extensions rather than step-up rounds, while personalized nutrition consolidates around fewer, better-capitalized players.